Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments

被引：9

作者：

Mbori-Ngacha, D

Richardson, BA

Overbaugh, J

Panteleeff, DD

Nduati, R

Steele, M

John-Stewart, G

机构：

[1] Univ Nairobi, Dept Pediat, Nairobi, Kenya

[2] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya

[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA

[4] Univ Washington, Dept Med, Seattle, WA USA

[5] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[6] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA

[7] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA

来源：

JOURNAL OF VIROLOGY | 2003年 / 77卷 / 13期

关键词：

D O I：

10.1128/JVI.77.13.7702-7705.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions.

引用

页码：7702 / 7705

页数：4

共 22 条

[1] The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 -: A meta-analysis of 15 prospective cohort studies [J].

Andiman, W ;

Boucher, M ;

Burns, D ;

Bryson, Y ;

Farley, J ;

Fowler, H ;

Gabiano, C ;

Galli, L ;

Hutto, C ;

Kind, C ;

Korber, B ;

Kovacs, A ;

Krogstad, P ;

Landesman, S ;

Lapointe, N ;

Lemay, M ;

Lew, J ;

Mandelbrot, L ;

Mayaux, MJ ;

Mellins, R ;

Minkoff, H ;

Mofenson, L ;

Nielsen, K ;

Newell, ML ;

Pardi, G ;

Peavy, H ;

Peckham, C ;

Read, J ;

Rother, C ;

Rudin, C ;

Scott, G ;

Semprini, A ;

Shearer, W ;

Simonds, R ;

Simpson, B ;

Stek, A ;

Tovo, PA ;

Tuomala, R ;

Van Dyke, R ;

Weedon, J ;

de Martino, M ;

Lindsay, M ;

Belair, S ;

Chan, L ;

Harris, D ;

Kalish, L ;

Muenz, L ;

Nugent, R ;

Schluchter, M ;

Durako, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (13) :977-987

[2]

[Anonymous], 2002, REPORT GLOBAL HIVAID

[3] The challenge of viral reservoirs in HIV-1 infection [J].

Blankson, JN ;

Persaud, D ;

Siliciano, RF .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :557-593

[4] Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection [J].

Cavert, W ;

Notermans, DW ;

Staskus, K ;

Wietgrefe, SW ;

Zupancic, M ;

Gebhard, K ;

Henry, K ;

Zhang, ZQ ;

Mills, R ;

McDade, H ;

Goudsmit, J ;

Danner, SA ;

Haase, AT .

SCIENCE, 1997, 276 (5314) :960-964

[5] Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission [J].

Chuachoowong, R ;

Shaffer, N ;

Siriwasin, W ;

Chaisilwattana, P ;

Young, NL ;

Mock, PA ;

Chearskul, S ;

Waranawat, N ;

Chaowanachan, T ;

Karon, J ;

Simonds, RJ ;

Mastro, TD .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :99-106

[6] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].

CONNOR, EM ;

SPERLING, RS ;

GELBER, R ;

KISELEV, P ;

SCOTT, G ;

OSULLIVAN, MJ ;

VANDYKE, R ;

BEY, M ;

SHEARER, W ;

JACOBSON, RL ;

JIMENEZ, E ;

ONEILL, E ;

BAZIN, B ;

DELFRAISSY, JF ;

CULNANE, M ;

COOMBS, R ;

ELKINS, M ;

MOYE, J ;

STRATTON, P ;

BALSLEY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180

[7] Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine [J].

Ekpini, RA ;

Nkengasong, JN ;

Sibailly, T ;

Maurice, C ;

Adjé, C ;

Monga, BB ;

Roels, TH ;

Greenberg, AE ;

Wiktor, SZ .

AIDS, 2002, 16 (04) :625-630

[8] Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya [J].

Emery, S ;

Bodrug, S ;

Richardson, BA ;

Giachetti, C ;

Bott, MA ;

Panteleeff, D ;

Jagodzinski, LL ;

Michael, NL ;

Nduati, R ;

Bwayo, J ;

Kreiss, JK ;

Overbaugh, J .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (07) :2688-2695

[9] HIGH-RISK OF HIV-1 INFECTION FOR 1ST-BORN TWINS [J].

GOEDERT, JJ ;

DULIEGE, AM ;

AMOS, CI ;

FELTON, S ;

BIGGAR, RJ .

LANCET, 1991, 338 (8781) :1471-1475

[10] Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].

Guay, LA ;

Musoke, P ;

Fleming, T ;

Bagenda, D ;

Allen, M ;

Nakabiito, C ;

Sherman, J ;

Bakaki, P ;

Ducar, C ;

Deseyve, M ;

Emel, L ;

Mirochnick, M ;

Fowler, MG ;

Mofenson, L ;

Miotti, P ;

Dransfield, K ;

Bray, D ;

Mmiro, F ;

Jackson, JB .

LANCET, 1999, 354 (9181) :795-802

← 1 2 3 →